believe be the from our point XXXX inflection earnings to II Phase important conference Thank you, and year year and continue as a Barbara program, and data fourth substantial our webcast Eloxx, company. cystic clinical which advance proof-of-concept we for full value welcome trial programs scientific to library line XXXX report and and a for will ERSG fibrosis Eloxx's will call. clinical our we for top be very quarter
our that actions fibrosis XXXX. which proof-of-concept have a through we to and top resources accomplish runway half sufficient deliver end company in of to key priority, the week, cystic to cystic to flexibility two run to ELX-XX capital that II first our the ensuring organizational the leadership commitment by years XXXX. strengthen of is of realignment in fibrosis and the These Phase has we ensure cash right announced data Last for the with strategic line the
will and in dominant with continue We also autosomal kidney enabling polycystic or retinal work disease disorders. inherited ADPKD
value safe continue expeditious delivering most to our needs manner. shareholders medical options fulfilling the to patients We provide mission be focused with and high to while to treatment unmet on in
opportunity critical develop to I'm parallel, company succession, In have a we fibrosis. retinal the inherited kidney development ERSG and lead other Phase advance ELX-XX library from Chief II compounds to in in Officer cystic program planned to at the we are our and for In diseases. I've Executive thrilled been this appointed time, as the continuing
and a the to resources assured is to led I'd goals. departing other affairs. and company's which prescribed who number Be Tymlos, stage. now regulatory osteoporosis. that with team recent and anabolic enabled the experienced to research our drug and employees, is most the the the have for Ward to the express personal which my postmenopausal like Bob to of company this one gratitude and the multiple advance expertise we we have I'm drugs, I confident of the that capabilities in basic have on development personally clinical strong deliver needed development, highly
of ensuring Phase and our cystic trials CF we this in year. half the committed clinical proof-of-concept top line are full In first of enrollment II fibrosis to reporting data
trials CF these at conducting are we top trial that pleased sites. clinical extremely are We
sites and has patient the program In been of investigators, level fact, and fibrosis groups support tremendous. interest top from for expressed our cystic efficacy trial
for pleased of group, very and cystinosis we CFF ELX-XX our our in completed we're the share positive clinical cystinosis. to the for of members we with discussion had cohort results view as trial patients data the points. of opportunity safety efficacy that recent and end a nephropathic the program first met safety exciting In advisory Phase They the II primary
trial, in CF program. derisk II data the further these with this of Phase Together support pharmacokinetics
We of additional we publications this be cadence data that as a will scientific there steady and expect year. through presentations move
will at from our presenting inherited the We Xth. be May retinal data through Xrd program disorders ARVO
part We Conference for been workshop Beyond Cystic titled: for of presentation gene presentation modulators: approaches in are will scientific the involving pleased early European editing accepted our and/or X that June Phase Fibrosis channels. on at trial our clinical has and ELX-XX be alternative a
Fibrosis We also late Cystic at North fibrosis plan to the American data cystic October. in in ELX-XX Conference for present
investigators X Phase trials: of open-label in sites at two CF enrolling program Europe Our clinical consists patients Israel. One for and
the X Europe, our by and the the been our Phase Society endorsement has sites in of the European funding In protocol been to Development second, made The Trial in by CF United part endorsed Foundation the Cystic trial focuses our U.S. Clinical by expansion Network. Therapeutic on possible States. by Cystic Fibrosis provided the Network. has Fibrosis protocol program The of
The MAD in than prior emerging administered profile the first safety renal greater from we indication based expected SAD, the kilogram these ELX-XX EL-XXX. In reported biologic for continued white blood consistent dose in patients a and per reductions at this those cohort endpoint line of X and cysteine top and nephropathic cystinosis, studies milligrams were of This day. met range. provide positive nominal study pharmacokinetics X.X cell study completed with supports of in data clear Phase the activity on ELX-XX the doses per primary development
events to In was well serious related nephrotoxicity, the deaths, ELX-XX no the study, tolerated generally ELX-XX. adverse with or ototoxicity potentially
met the human clinical approved Committee and that of proof-of-concept patients XX and our the biologic to of would other ERSG enable enrolling review believe results We activity of the first and ages progressing safety Safety that and second for provides Review the independent pharmacokinetic applications cohort completion derisks older. library. clarification to cohort, ELX-XX Following the
ELX-XX it cell cysteine white pretreatment levels, contemplated cell will protocol. mediated elevated the with made in uncontrolled study However, design the original we and have cysteine evaluate all blood as across Therefore, groups and study blood due which dose to white second fully reductions. proceed discontinued cohort the to limitations, patients not had difficult
with We are new experts possible these to to design. and for a continuing determine panel clinical of review appropriate study scientific modifications data
Last Society Eloxx expansion Week necessary dose The research our the kidney ADPKD. function. nephropathic of Nephrology presented data new provides other beyond based renal renal on adjustments quarter, also into the of the positive our American modeling study, for Kidney scientific supports during such completed from areas data team as impairment which in cystinosis
indications continue ERSG our molecules novel evaluate Our opportunities advance or to library. programs the other for from new ELX-XX screening to
and important restore an an our the that We ERSG milestone injected proof-of-concept continue in achieved intravitreally to can our advance compounds our work demonstrating model. production ophthalmology in protein team when animal in eye
ongoing to will periods. sustain formulation build compound longer treatment milestone on across our exposure We this efforts with
CEPXXX, are nonsense Usher the the We alleles of for read-through genes. most disorders and syndrome and of evaluating photoreceptors other common demonstrating PDEXB recently the RPE MYOXA or
that ADPKD our into of there's We mutation encouraging research such where ongoing a kidney expanding diseases high from believe the support prevalence as results into cystinosis study our nonsense patients.
most programs challenge scientific community. There's nonsense business We the advanced mutations. tackling for and and level developing as in potential interest high new for clinical therapies the of the are our a community the as enthusiasm of well great in company
cash ended pursuing expand progress. in business actively XXXX cash footprint $XX.X and relationships engaged million equivalents. accelerate strategic We in with therapeutic to our remain We and our
the cash through to will XXXX. take years, of the resources, of extended With runway our end we've two realignment which our us
our ELX-XX We deliver the and to and to preclinical advance to in for indications. funded for advance data our are programs in activities well molecules additional ELX-XX library clinical line top cystic fibrosis of
in Medical who'll our kidney Haverty, I'd now like work provide programs Phase Officer, the update to in Chief disease. a advances Dr. introduce further and our with you our Tom discuss X genetic on
